

STATEMENT OF WOLFGANG HINZ


I, Wolfgang Hinz, in making this statement of my own personal knowledge and information, attest as follows:

1. I am a medicinal chemist skilled in the art.
2. I studied Chemistry and Biochemistry during my undergraduate work at the University of Cape Town, South Africa.
3. I studied synthetic organic chemistry during my graduate work at the University of Cape Town, South Africa.
4. I studied structure-based drug design during my postgraduate work at Yale University, New Haven, CT.
5. I have worked as Senior Scientist at the Rothberg Institute for Childhood Diseases for 7 years.
6. I have worked as Director of Chemistry at Ion Torrent Systems, Inc. for 2 years.
7. I worked as Director of Chemistry at Life Technologies Inc. for 4 years.
8. I have worked as Senior Director at Thermo Fisher Scientific for 4 years.
9. I have been named inventor on 86 granted US patents, largely pertaining to chemistry and biochemistry.
10. I have been named inventor on 144 US patent applications, largely pertaining to chemistry and biochemistry.
11. Having reviewed the precedential medical history, and based on my knowledge and experience as one skilled in the art, it is my opinion that there is a substantial risk that the ranitidine molecule will degrade into dimethylamine (“DMA”) and be a source of nitrite (“N”).
12. Both chemical components and precursors of NDMA – nitrite (“N”) and dimethylamine

("DMA") -- are present in the ranitidine molecule, and it is my opinion that the terminal tertiary amine is vulnerable to degradation.

13. Once liberated, the N and DMA could combine in physiological conditions to form NDMA.

14. The potential for such a chemical reaction based on the chemical nature of the ranitidine molecule is sufficiently high to demand further study.

 7/30/2019.

Wolfgang Hinz